Dova Pharmaceuticals to Present at Upcoming Investor Conferences
DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company overviews at two upcoming investor conferences:
- H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 12:30 p.m. ET in New York, NY.
- Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 2:30 p.m. ET in New York, NY.
A live audio webcast of each event will be available via the "Investor Relations" page of the Dova website, . Please log on through Dova's website approximately 10 minutes before the scheduled start times. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s proprietary pipeline includes one commercial product, DOPTELET®, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure and the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. For more information, visit .
Contacts
Mark W. Hahn
Chief Financial Officer
(919) 338-7936
Westwicke
John Woolford
(443) 213-0506
